REMARKS/ARGUMENTS

Response to the Restriction Requirement

In response to the Restriction Requirement, the Applicants elect Group II, claims 16 to 33 drawn to a composition comprising a PPARα agonist and a CB1 receptor antagonist, classified in class 514, subclass 762.

Regarding the election of a species of CB1 receptor antagonist, the Applicants elect Rimonabant (see antagonist of claim 19). Regarding the election of a species of PPAR α agonist, the Applicants elect OEA, the compound of claim 17.

As amended, all the composition claims except for claim 32 read on the elected subject matter.

Status of the Claims

Claims 1 to 35 were previously pending. Claims 1 to 15 and 34 to 36 stand withdrawn. Claims 20, 29, and 34 are herein amended. Claim 36 is newly presented. After entry of these amendments claims 16 to 33 will be undergoing examination and claims 1 to 15 and 34 to 36 will stand withdrawn.

Support for the Amendment to the Claims

Claim 20 was amended to change its dependency from claim 17 to claim 16. This amendment provides the correct antecedent basis for the PPAR α subject matter of claim 20. Support is found in the previous versions of these claims as well as paragraph 42.

Claim 29 was amended to correct a typographical error and to conform with its antecedent basis as set forth in claim 20. Support for this subject matter is also found in paragraphs 138 and 145.

Linking claim 34 was amended to change its dependency from claim 17 to 16. Support for this subject matter is found in the specification at paragraph 28.

New claim 36 sets forth subject matter of previous claim 34.

In view of the above, the Applicants believe the Amendments to the claims add no new matter and respectfully request their entry.

Appl. No. 10/642,462 Amdt. dated December 19, 2006 Reply to Office Action of August 22, 2006

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 925-472-5000.

Respectfully submitted,

Frank J. Mycroft Reg. No. 46,946

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834

Tel: 925-472-5000 Fax: 415-576-0300

Attachments FJM:fjm 60942318 v3